Overview

A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2

Status:
Unknown status

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

Summary

A multi-sites study about the efficacy of sequential monotherapy: Capecitabine vs. endocrine therapy, in metastatic breast cancer patients with HR-positive & HER2-negative after capecitabine-base chemotherapy.

Phase:

N/A

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Collaborators:

307 Hospital of PLA
Fudan University
Fujian Province Tumor Hospital
Hangzhou Cancer Hospital
Jiangsu Provincial People's Hospital
Sir Run Run Shaw Hospital
The Tumor Hospital of Jiangsu Province
Zhejiang Chinese Medical University
Zhejiang University

Treatments:

Capecitabine
Hormones